Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease

Author(s): Justin Longenberger, Zahoor A. Shah

Journal Name: Current Alzheimer Research

Volume 8 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


Alzheimers disease, one of the most common forms of dementia, is a neurodegenerative disorder characterized by progressive cognitive decline and affects as many as 5.3 million people in United States alone. Both Alzheimers and dementia have tripled the cost of health care for elderly people, amounting to about $148 billion each year. Although there have been numerous drugs designed so far, no ideal or successful drug treatment for Alzheimers and dementia has been translated into clinical setups. One of the most widely accepted theories of Alzheimers pathology is the aggregation of amyloid-beta (Aβ) into extracellular cortical and hippocampal plaques. It has also been postulated that excessive cholesterol build-up in the brain plays an integral role in Aβ aggregation, and using HMG-coA reductase inhibitors may reduce Aβ accumulation by lowering brain cholesterol levels. Based on the success of animal studies and phase II clinical trials, HMG-coA reductase inhibitors may provide a viable alternative therapy in AD treatment. This review highlights the results of both pre-clinical and clinical trials on HMG-coA reductase inhibitors in order to give a comprehensive overview of their recent progress in Alzheimers disease research.

Keywords: Alzheimer's disease, cholesterol, HMG-coA reductase inhibitors, amyloid-beta, dementia, gemma-secretase, C-terminal fragment, glutamatergic function, L-DOPA

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [434 - 442]
Pages: 9
DOI: 10.2174/156720511795745393
Price: $65

Article Metrics

PDF: 12